|
Cascadian Therapeutics Inc (ONTY) Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. Co.'s clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting the Mucin 1 peptide antigen. Co. also develops preclinical product candidates in oncology, and potentially certain rare diseases, using its acquired protocell technology. Co. also collaborates with partners to discover and develop additional product candidates.
|
|